Novo Nordisk discovers and develops innovative medicines and makes them accessible to patients throughout the world. Nearly a century of innovation and leadership has led to the development of a comprehensive portfolio of products and delivery systems for diabetes care, as well as in other therapeutic areas where the company can make a difference.
Access each of our location pages below to read more about our sites within the U.S. and learn more about our company’s History.
Diabetes Finished Products (DFP) helps support Novo Nordisk as a
leader in diabetes by providing a complete product portfolio of
insulin and GLP-1 products.
Diabetes Active Pharmaceutical Ingredients (DAPI) will support Novo Nordisk in production and engineering.